The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Co-Administered With Atorvastatin, in Subjects with Hypertriglyceridemia 4 g/day 16 weeks NCT00435045 Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid-Ethyl Esters) in Recurrent ...

Ranbaxy reportedly reaped $500 million in sales from its knockoff of Pfizer's cholesterol pill Lipitor during its first ... and innovation for the future. Sanofi has taken a small step towards ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

News for Sanofi India Ltd. CD&R Acquires 26% Stake in Sanofi Consumer Healthcare India - Rs 2,983 Cr Open Offer Global investment firm CD&R has announced an open offer to acquire a 26% stake ...

NVIDIA logos are seen on equipment on display at Computex in Taipei, Taiwan June 5, 2024. REUTERS/Ann Wang/File Photo Nvidia Corp's results in the coming week could guide the U.S. stock market on ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,230.97 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...